Arix Bioscience notes Harpoon Therapeutics' immuno-oncology collaboration with AbbVie
October 18 2017 - 7:34AM
Arix Bioscience notes Harpoon Therapeutics'
immuno-oncology collaboration with AbbVie
LONDON, 18 October 2017: Arix Bioscience
plc (LSE: ARIX) ("Arix Bioscience"), a global healthcare and life
science company supporting medical innovation, is pleased to note
that Harpoon Therapeutics ("Harpoon"), an Arix Bioscience Group
Business, and AbbVie (NYSE: ABBV) have entered into an
immune-oncology research collaboration.
The goal of the research collaboration is to
incorporate Harpoon's novel tri-specific T-cell activating
construct (TriTAC(TM)) platform with AbbVie's research-stage
immune-oncology targets to develop innovative cancer therapies.
Under the terms of the agreement, Harpoon will
engineer and evaluate TriTAC molecules directed against selected
cancer targets, and provide AbbVie the right to pursue further
development and commercialisation of these molecules. Financial
terms were not disclosed.
Joe Anderson, Chief Executive Officer of Arix
Bioscience, commented: "The collaboration with AbbVie is
encouraging validation of Harpoon's novel T-cell engaging platform
approach. This further reinforces our belief in the potential of
Harpoon to discover and develop important new therapies to fight
cancer."
For more information, please contact:
Arix Bioscience plcJoe Anderson, CEO+44
(0) 20 7290 1052
Matthew Cole, Communications Director+44 (0) 20
7290 1065
Consilium Strategic
CommunicationsMary-Jane Elliott, Jessica Hodgson, Ivar
Milligan+44 (0)20 3709 5700arix@consilium-comms.com
About Arix Bioscience plcArix Bioscience
plc is a global healthcare and life science company supporting
medical innovation. Headquartered in London and with an
office in New York, Arix Bioscience sources, finances and
builds world class healthcare and life science businesses
addressing medical innovation at all stages of development.
Operations are supported by privileged access to breakthrough
academic science and strategic relationships with leading research
accelerators and global pharmaceutical companies.
Arix Bioscience plc is listed on the Main Market
of the London Stock Exchange.
For further information, please
visit www.arixbioscience.com.
About Harpoon Therapeutics
Harpoon Therapeutics is an immuno-oncology
company founded by Patrick Baeuerle, PhD, a pioneer in the
development of T-cell engaging therapies, and MPM Capital. The
company is focused on the discovery and development of novel T-cell
engaging biologics for the treatment of cancer and other diseases.
Harpoon Therapeutics created a novel T-cell recruiting drug
discovery platform called TriTAC (tri-specific T-cell activating
construct) to unleash the targeted cell-killing properties of a
patient's own immune system through T-cell activation. This
approach is being optimized to penetrate tissues and extend serum
exposure, and has the potential to address a broad range of
cancers, including solid tumors, and immunologic diseases. HPN424,
a prostate-specific membrane antigen (PSMA)-targeting TriTAC
biologic, is in development for the treatment of prostate cancer
and is expected to enter a clinical trial in 2018. For more
information, please visit www.harpoontx.com.
About AbbVie AbbVie is a global,
research-driven biopharmaceutical company committed to developing
innovative advanced therapies for some of the world's most complex
and critical conditions. The company's mission is to use its
expertise, dedicated people and unique approach to innovation to
markedly improve treatments across four primary therapeutic areas:
immunology, oncology, virology and neuroscience. In more than
75 countries, AbbVie employees are working every day to advance
health solutions for people around the world. For more information
about AbbVie, please visit us at www.abbvie.com. Follow
@abbvie on Twitter, Facebook or LinkedIn.
Arix Bioscience (LSE:ARIX)
Historical Stock Chart
From Apr 2024 to May 2024
Arix Bioscience (LSE:ARIX)
Historical Stock Chart
From May 2023 to May 2024